Genmab Balance Sheet Health
Financial Health criteria checks 6/6
Genmab has a total shareholder equity of DKK5.3B and total debt of DKK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are DKK6.6B and DKK1.3B respectively. Genmab's EBIT is DKK7.2B making its interest coverage ratio -8.3. It has cash and short-term investments of DKK3.2B.
Key information
0%
Debt to equity ratio
DKK 0
Debt
| Interest coverage ratio | -8.3x |
| Cash | DKK 3.23b |
| Equity | DKK 5.30b |
| Total liabilities | DKK 1.29b |
| Total assets | DKK 6.59b |
Recent financial health updates
No updates
Recent updates
Genmab's Outlook Beyond Darzalex's Patent Cliff
Apr 15Genmab: GEN3014's Demise And Implications For The HexaBody Platform
Mar 14Genmab Is Too Attractive To Ignore
Dec 08Genmab: Looking To Manage My Position Around Q3 Earnings
Nov 06Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab
Aug 23Genmab: A Complicated Tale
May 01Genmab Acquires A Missing Piece For Its Pipeline
Apr 16Genmab: Recent Updates Support The Growth Narrative
Feb 21Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade)
Jan 23Genmab: 3 Trends To Track For A Strong 2024 And Beyond
Jan 12Genmab reports Q3 worldwide sales of $2.05B for Darzalex
Oct 18Genmab improves FY 2022 guidance
Aug 08Genmab reports Q2 worldwide net sales of DARZALEX $1.99B
Jul 19Genmab: A Royalty Powerhouse With A Strong Pipeline
Jun 28Financial Position Analysis
Short Term Liabilities: GMAB's short term assets (DKK4.0B) exceed its short term liabilities (DKK756.0M).
Long Term Liabilities: GMAB's short term assets (DKK4.0B) exceed its long term liabilities (DKK534.0M).
Debt to Equity History and Analysis
Debt Level: GMAB is debt free.
Reducing Debt: GMAB has not had any debt for past 5 years.
Debt Coverage: GMAB has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: GMAB has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/22 04:33 |
| End of Day Share Price | 2025/05/22 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genmab A/S is covered by 47 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Carlsen | ABG Sundal Collier |
| Armelle Moulin | AlphaValue |
| Xue Chen | Barclays |